← Leaderboards
Margie L. Clapper
Fox Chase Cancer Center
$16,783,564
Attributed
$17,179,435
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,419,783 · 22
By mechanism
R01$11,179,287 · 6
U54$6,863,105 · 5
N01$2,574,478 · 4
R21$1,167,942 · 3
R03$342,136 · 2
P30$292,835 · 2
Top collaborators
- Carmen Sapienza2 shared
- Kunwar Shailubhai2 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Igor Astsaturov$3,975,720
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCancer PreventionBasePathway InteractionsPreventiveInsightMutationMolecular TargetIncidenceTumorCancer RiskAttentionLeadLesionInflammationMouse ModelGeneticProgramsClinically RelevantMolecularGenesColonChemopreventionColon Carcinoma
Grant awards (66)
Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center$1,431,641
U54 · FY2025 · CA · contact PI
Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis$648,814
R01 · FY2025 · CA · contact PI
Administrative Core$258,877
U54 · FY2025 · CA · contact PI
Cancer Prevention and Control Program$66,524
P30 · FY2025 · CA · contact PI
Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center$1,170,059
U54 · FY2024 · CA · contact PI
Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis$525,677
R01 · FY2024 · CA · contact PI
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA$515,612
N01 · FY2024 · CA · contact PI
Administrative Core$245,934
U54 · FY2024 · CA · contact PI
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome$200,000
U54 · FY2024 · CA · contact PI
Novel small molecule agents to correct pathogenic VHL missense mutations$200,000
U54 · FY2024 · CA · contact PI
TO Title: Contract Orientation & Kickoff Meeting for Preclinical Services for PREVENT Base IDIQ Title: PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate E$3,500
N01 · FY2024 · CA · contact PI
Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center$1,207,007
U54 · FY2023 · CA · contact PI
Colorectal Cancer (CRC) Prevention by Urolithin A in Rodent CRC models$1,038,958
N01 · FY2023 · CA · contact PI
Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis$484,469
R01 · FY2023 · CA · contact PI
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome$406,353
U54 · FY2023 · CA · contact PI
Administrative Core$252,717
U54 · FY2023 · CA · contact PI
Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center$1,231,641
U54 · FY2022 · CA · contact PI
Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis$423,946
R01 · FY2022 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$419,207
R01 · FY2022 · CA · contact PI
Administrative Core$258,876
U54 · FY2022 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$179,359
R01 · FY2022 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$427,763
R01 · FY2021 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$199,155
R01 · FY2021 · CA · contact PI
Cancer Prevention and Control Program (05)$14,265
P30 · FY2021 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$427,763
R01 · FY2020 · CA · contact PI
Cancer Prevention and Control Program (05)$42,035
P30 · FY2020 · CA · contact PI
Cancer Prevention and Control Program (05)$8,695
P30 · FY2020 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$414,929
R01 · FY2019 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$406,054
R01 · FY2019 · CA · contact PI
Cancer Prevention and Control Program (05)$39,326
P30 · FY2019 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$418,613
R01 · FY2018 · CA · contact PI
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites$418,613
R01 · FY2018 · CA · contact PI
Cancer Prevention and Control Program (05)$35,558
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control Program (05)$10,869
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control Program (05)$5,966
P30 · FY2018 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$418,613
R01 · FY2017 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$175,899
R01 · FY2017 · CA · contact PI
Cancer Prevention and Control Program (05)$35,557
P30 · FY2017 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$408,319
R01 · FY2016 · CA · contact PI
Cancer Prevention and Control Program (05)$34,040
P30 · FY2016 · CA · contact PI
Targeted Chemoprevention of Flat and Polypoid Colitis-associated Dysplasias$408,319
R01 · FY2015 · CA · contact PI
Folic Acid Supplementation and Prevention of Colitis-Associated Colorectal Cancer$221,775
R21 · FY2015 · CA · contact PI
Folic Acid Supplementation and Prevention of Colitis-Associated Colorectal Cancer$194,119
R21 · FY2014 · CA · contact PI
GC-C Agonists: Specific Probes for the Detection of Colorectal Tumors$199,269
R21 · FY2013 · CA
CYP1B1: A Molecular Target for Chemoprevention of Lung Adenocarcinoma$83,895
R03 · FY2013 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$359,108
R01 · FY2012 · CA · contact PI
GC-C Agonists: Specific Probes for the Detection of Colorectal Tumors$176,579
R21 · FY2012 · CA
CYP1B1: A Molecular Target for Chemoprevention of Lung Adenocarcinoma$89,250
R03 · FY2012 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$351,225
R01 · FY2011 · CA · contact PI
Preclinical Efficacy and Intermediate Endpoint Assays$1,016,408
N01 · FY2010 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$362,088
R01 · FY2010 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$664,093
R01 · FY2009 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$361,915
R01 · FY2009 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$349,000
R01 · FY2009 · CA · contact PI
Chemoprevention of Colitis-Associated Neoplasia by 5-ASA$360,013
R01 · FY2008 · CA · contact PI
Colonoscopic Analysis of Response of Murine Colon Lesions to Drug Intervention$171,000
R21 · FY2008 · CA · contact PI
Colonoscopic Analysis of Response of Murine Colon Lesions to Drug Intervention$205,200
R21 · FY2007 · CA · contact PI
Disruption of Glutathione S-Transferase M1 in Mice$83,491
R03 · FY2006 · CA · contact PI
Disruption of Glutathione S-Transferase M1 in Mice$85,500
R03 · FY2005 · CA
Analysis of the Chemopreventive Activity of FGN 1$313,740
R01 · FY2004 · CA
Analysis of the Chemopreventive Activity of FGN 1$313,740
R01 · FY2003 · CA
Imaging Molecular Changes during Colon Tumorigenesis$0
U54 · FY2003 · CA
Analysis of the Chemopreventive Activity of FGN 1$315,607
R01 · FY2002 · CA
Analysis of the Chemopreventive Activity of FGN 1$321,677
R01 · FY2001 · CA
PHASE II CLINICAL TRIALS OF NEW CHEMOPREVENTIVE AGENTS$0
N01 · FY2001 · CN
GLUTATHIONE S-TRANSFERASE M AND CANCER SUSCEPTIBILITY$301,569
R01 · FY2000 · CA